Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2005

View Archived Issues

Efficacy of the natural triterpene product BSP-103 demonstrated in patients with psoriasis

Antiirritative efficacy of licochalcone shown in volunteers with induced erythema

Efficacy of DA-9102 as a treatment for atopic dermatitis shown in NC/Nga mice

Favorable efficacy, safety, pharmacokinetic profiles reported on anti-IL-12p40 in psoriasis patients

Eligard six-month formulation now available

Atugen and Altana renew target validation and license agreement

Affinium selects new development candidate as MRSA antibiotic

Xechem makes progress in Nicosan/Hemoxin efforts

Teva exercises option for StemEx codevelopment

Treatment begins in phase I liver cancer study of ThermoDox

Enrollment open in phase II study of Virostat for hepatitis C

EuroVacc 02 HIV vaccine trial begins

STELLAR 3 results due early

IDEA-070 studied in phase II trial for inflammatory skin diseases

Priority review for Keppra in childhood epilepsy

Chemgenex licenses platinum compound from M. D. Anderson

Update on the effects and safety of degarelix

Good safety profile of MDX-010 in patients with relapsing malignancies after allo-HCT

New clinical data on the efficacy of CG-53135-05 in the prevention of chemotherapy-induced mucositis

Posaconazole shows efficacy against fungal infections in patients scheduled to undergo HSCT

Xeloda receives positive opinion in Europe for colon cancer post surgery

New positive opinion for Cymbalta in Europe

Novel Bcr-Abl kinase inhibitor described / News in Context

Report from FDA COX-2 safety review

New Mitsubishi Pharma drugs prevent post-chemotherapy hypersensitivity reactions

Aventis reports new NHE-1 inhibitors for angina pectoris and related disorders

Novel anti-hepatitis C virus agents developed by Anadys researchers

New antiinfective monoclonal antibodies and their use reported by Alexion

Boehringer Ingelheim imparts new DPP-IV inhibitors for the treatment of diabetes

Novel antiproliferative agents disclosed by Bayer scientists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...